Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer

被引:8
|
作者
Nicos, Marcin [1 ]
Krawczyk, Pawel [1 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, PL-20954 Lublin, Poland
关键词
NSCLC; tumor evolution; driver mutations; clonal; subclonal alterations; metastases; STEM-CELLS; INTRATUMOR HETEROGENEITY; MESENCHYMAL TRANSITION; TUMOR EVOLUTION; BRANCHED EVOLUTION; BRAIN METASTASES; T790M MUTATION; CD133(+) CELLS; ADENOCARCINOMA; NOTCH;
D O I
10.3390/cancers14071813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Limited knowledge about NSCLC evolution has affected therapeutic strategies for many decades. The application of NGS-based techniques to studies on ITH has provided genetic insight into the contribution of clonality primary seeding, as well as to distant dissemination. To date, multiregional ITH affects accurate diagnosis and treatment decisions and is considered the main hallmark of anticancer therapy failure. Understanding the evolutionary trajectories that drive the metastatic process is critical for improving treatment strategies for this deadly condition. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC, highlighting that wide genetic analyses may reveal the phylogenetic lineages of NSCLC evolution. Data indicate that many driver alterations from the primary tumor of non-small cell lung cancer (NSCLC) are predominantly shared across all metastases; however, disseminating cells may also acquire a new genetic landscape across their journey. By comparing the constituent subclonal mutations between pairs of primary and metastatic samples, it is possible to derive the ancestral relationships between tumor clones, rather than between tumor samples. Current treatment strategies mostly rely on the theory that metastases are genetically similar to the primary lesions from which they arise. However, intratumor heterogeneity (ITH) affects accurate diagnosis and treatment decisions and it is considered the main hallmark of anticancer therapy failure. Understanding the genetic changes that drive the metastatic process is critical for improving the treatment strategies of this deadly condition. Application of next generation sequencing (NGS) techniques has already created knowledge about tumorigenesis and cancer evolution; however, further NGS implementation may also allow to reconstruct phylogenetic clonal lineages and clonal expansion. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC. We highlight that wide genetic analyses may reveal the phylogenetic trajectories of NSCLC evolution, and may pave the way to better management of follow-up and treatment.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Paclitaxel for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (08) : 1771 - 1780
  • [22] Vinorelbine for non-small cell lung cancer
    Piccirillo, Maria Carmela
    Daniele, Gennaro
    Di Maio, Massimo
    Bryce, Jane
    De Feo, Gianfranco
    Del Giudice, Antonia
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT OPINION ON DRUG SAFETY, 2010, 9 (03) : 493 - 510
  • [23] Immunotherapy for non-small cell lung cancer
    Kagamu, Hiroshi
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 307 - 312
  • [24] Radiotherapy for non-small cell lung cancer
    Jassem, J
    LUNG CANCER, 2001, 34 : S177 - S180
  • [25] Psoas muscle metastases in non-small cell lung cancer
    Strauss, Jonathan B.
    Shah, Anand P.
    Chen, Sea S.
    Gielda, Benjamin T.
    Kim, Anthony W.
    JOURNAL OF THORACIC DISEASE, 2012, 4 (01) : 83 - 87
  • [26] Emepepimut-S for non-small cell lung cancer
    Corrales-Rodriguez, Luis
    Blais, Normand
    Soulieres, Denis
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (08) : 1091 - 1097
  • [27] Non-small cell lung cancer in the elderly
    Makrantonakis, PD
    Galani, E
    Harper, PG
    ONCOLOGIST, 2004, 9 (05) : 556 - 560
  • [28] Sorafenib in non-small cell lung cancer
    Zhang, Jianjun
    Gold, Kathryn A.
    Kim, Edward
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (09) : 1417 - 1426
  • [29] Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Mambetsariev, Isa
    Arvanitis, Leonidas
    Fricke, Jeremy
    Pharaon, Rebecca
    Baroz, Angel R.
    Afkhami, Michelle
    Koczywas, Marianna
    Massarelli, Erminia
    Salgia, Ravi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [30] Resectable non-small cell lung cancer: an evolving landscape
    Loh, Jerold
    Wijaya, Silvana T.
    Sooi, Kenneth
    Chia, Puey Ling
    Soo, Ross A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (07) : 1241 - 1246